Reig Jofre contributes its know-how in the development of biological vaccines to the innovative consortium of Vaxdyn
- Vaxdyn’s project to develop a new multi-antigen vaccine against serious bacterial infections, including pneumonia, is in early stages, and is funded by CARB-X, global biopharmaceutical accelerator to combat antibiotic resistance
- Reig Jofre along with the National Center of Microbiology of the Spanish Institute of Health Carlos III are part of the consortium led by the biotech Vaxdyn
- An estimated 700,000 people die each year from drug-resistant bacterial infections, and the death toll is expected to rise unless new preventatives and treatments are found
Reig Jofre, a pharmaceutical company listed on the Spanish continuous market, participates in the based in Seville, Spain biotech Vaxdyn consortium to develop a new multi-antigen vaccine against serious bacterial infections caused by Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, which could prevent antibiotic-resistant pneumonia in patients with elevated risk , such as those affected by chronic lung diseases, diabetes or undergoing cancer treatment.
With an extensive experience of more than 10 years in pharmaceutical development, industrial scaling of innovative injectable biological products that require specialization to stabilize by lyophilization, Reig Jofre will contribute to this consortium its expertise in the analytical strategy, quality control and definition of the process for the production of clinical batches and guarantee the subsequent industrial scale-up of the vaccine of Vaxdyn.